GSK3B and Alzheimer disease: The activation of GSK-3β through the phosphorylation of tyrosine 216 and serine 9 is regulated by signaling pathways such as PI3K/Akt and Wnt/β-catenin, which may be dysregulated in AD, leading to increased GSK-3β activity [5,13,16].